This latest approval moves the company's biosimilar portfolio a notch higher in the lucrative Chinese market.
Suzhou, China-based Innovent Biologics said that its adalimumab biosimilar (Sulinno) has received marketing approval from China’s National Medical Products Administration (NMPA).
“The launch of Sulinno once again fulfilled our mission to develop and commercialize high quality biopharmaceutical products that are affordable to ordinary people. We hope that this product will benefit more and more patients and families in need and improve their quality of life,” Michael Yu, chairman and CEO of Innovent, said in a statement.
The drug referencing Humira is a recombinant human anti–tumor necrosis factor–alpha monoclonal antibody injection. Sulinno has been approved by the NMPA for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis.
In China, there are nearly 20 million patients with rheumatoid arthritis, ankylosing spondylitis, or psoriasis, according to Innovent.
Although the reference product is widely used in North America and Europe, Humira’s high costs make it difficult for the average patient in China to afford this drug, resulting in limited access to the medicine.
“The launch of Sulinno will provide more Chinese patients with high-quality and relatively affordable adalimumab injection[s], bringing hope and opportunities to more patients,” Innovent said.
Innovent’s Growing Portfolio
This is Innovent’s third monoclonal antibody to be approved by the NMPA. Tyvyt (sintilimab) received Chinese approval in 2019 and Byvasda (bevacizumab) received approval in June 2020.
Byvasda was approved in China for the treatment of non–small cell lung cancer, metastatic colorectal cancer, glioblastoma, renal cell carcinoma, cervical cancer, and epithelial ovarian, fallopian tube, or primary peritoneal cancer.
In January 2019, Innovent announced that Tyvyt, developed in partnership with Eli Lilly, had received NMPA approval for the treatment of Hodgkin lymphoma.
In May 2019, Innovent’s rituximab biosimilar candidate (IBI301), also developed in partnership with Eli Lilly, met primary end points in a phase 3 pharmacokinetic clinical trial. In June 2019, Eli Lilly announced that the NMPA accepted an application for IBI301’s marketing approval.
IBI301 references Rituxan, which is indicated for the treatment of non-Hodgkin lymphoma, chronic lymphocytic leukemia, granulomatosis with polyangiitis, and microscopic polyangiitis.
In addition to its biosimilar and novel biologics portfolio, Innovent also is developing an antibody treatment for coronavirus disease 2019 (COVID-19), according to the Milken Institute’s COVID-19 tracker.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Alvotech’s Stelara Biosimilar, Selarsdi, Receives FDA Approval
April 16th 2024Alvotech’s Selarsdi (ustekinumab-aekn), a biosimilar referencing Stelara (ustekinumab), gained FDA approval, making it the second ustekinumab biosimilar and second for the company to be given the green light for the American market.
Decoding the Patent Puzzle: Navigating the Legal Landscape of Biosimilars
March 17th 2024On this episode of Not So Different, Ha Kung Wong, JD, an intellectual patent attorney and partner at Venable LLP, details the confusing landscape that is the US patent system and how it can be improved to help companies overcome barriers to biosimilar competition.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
Sintilimab, Bevacizumab Biosimilar, HAIC Improves Survival in Patients With Unresectable HCC
April 14th 2024Positive results of sintilimab, IBI305, and hepatic arterial infusion chemotherapy (HAIC) treatment showed shrinking tumors and previously converting inoperable hepatocellular carcinoma (HCC) to resectable HCC with manageable adverse effects.